Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: Novel type II inhibitor of gatekeeper mutants

Ellen Weisberg, Hwan Geun Choi, Arghya Ray, Rosemary Barrett, Jianming Zhang, Taebo Sim, Wenjun Zhou, Markus Seeliger, Michael Cameron, Mohammed Azam, Jonathan A. Fletcher, Maria Debiec-Rychter, Mark Mayeda, Daisy Moreno, Andrew L. Kung, Pasi Antero Janne, Roya Khosravi-Far, Junia V. Melo, Paul W. Manley, Sophia AdamiaCatherine Wu, Nathanael Gray, James D. Griffin

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Many clinically validated kinases, such as BCR-ABL, c-Kit, PDGFR, and EGFR, become resistant to adenosine triphosphate-competitive inhibitors through mutation of the so-called gatekeeper amino acid from a threonine to a large hydrophobic amino acid, such as an isoleucine or methionine. We have developed a new class of adenosine triphosphate competitive inhibitors, exemplified by HG-7-85-01, which is capable of inhibiting T315I-BCR-ABL (clinically observed in chronic myeloid leukemia), T670I-c-Kit (clinically observed in gastrointestinal stromal tumors), and T674I/M-PDGFRα (clinically observed in hypereosinophilic syndrome). HG-7-85-01 is unique among all currently reported kinase inhibitors in having the ability to accommodate either a gatekeeper threonine, present in the wild-type forms of these kinases, or a large hydrophobic amino acid without becoming a promiscuous kinase inhibitor. The distinctive ability of HG-7-85-01 to simultaneously inhibit both wild-type and mutant forms of several kinases of clinical relevance is an important step in the development of the next generation of tyrosine kinase inhibitors.

Original languageEnglish
Pages (from-to)4206-4216
Number of pages11
JournalBlood
Volume115
Issue number21
DOIs
Publication statusPublished - 2010 May 27
Externally publishedYes

Fingerprint

src-Family Kinases
Phosphotransferases
Molecules
Threonine
Amino Acids
Adenosine Triphosphate
Hypereosinophilic Syndrome
Gastrointestinal Stromal Tumors
Isoleucine
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Methionine
Protein-Tyrosine Kinases
Tumors
Mutation

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases : Novel type II inhibitor of gatekeeper mutants. / Weisberg, Ellen; Choi, Hwan Geun; Ray, Arghya; Barrett, Rosemary; Zhang, Jianming; Sim, Taebo; Zhou, Wenjun; Seeliger, Markus; Cameron, Michael; Azam, Mohammed; Fletcher, Jonathan A.; Debiec-Rychter, Maria; Mayeda, Mark; Moreno, Daisy; Kung, Andrew L.; Janne, Pasi Antero; Khosravi-Far, Roya; Melo, Junia V.; Manley, Paul W.; Adamia, Sophia; Wu, Catherine; Gray, Nathanael; Griffin, James D.

In: Blood, Vol. 115, No. 21, 27.05.2010, p. 4206-4216.

Research output: Contribution to journalArticle

Weisberg, E, Choi, HG, Ray, A, Barrett, R, Zhang, J, Sim, T, Zhou, W, Seeliger, M, Cameron, M, Azam, M, Fletcher, JA, Debiec-Rychter, M, Mayeda, M, Moreno, D, Kung, AL, Janne, PA, Khosravi-Far, R, Melo, JV, Manley, PW, Adamia, S, Wu, C, Gray, N & Griffin, JD 2010, 'Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: Novel type II inhibitor of gatekeeper mutants', Blood, vol. 115, no. 21, pp. 4206-4216. https://doi.org/10.1182/blood-2009-11-251751
Weisberg, Ellen ; Choi, Hwan Geun ; Ray, Arghya ; Barrett, Rosemary ; Zhang, Jianming ; Sim, Taebo ; Zhou, Wenjun ; Seeliger, Markus ; Cameron, Michael ; Azam, Mohammed ; Fletcher, Jonathan A. ; Debiec-Rychter, Maria ; Mayeda, Mark ; Moreno, Daisy ; Kung, Andrew L. ; Janne, Pasi Antero ; Khosravi-Far, Roya ; Melo, Junia V. ; Manley, Paul W. ; Adamia, Sophia ; Wu, Catherine ; Gray, Nathanael ; Griffin, James D. / Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases : Novel type II inhibitor of gatekeeper mutants. In: Blood. 2010 ; Vol. 115, No. 21. pp. 4206-4216.
@article{d97d60bfc5024f269b43716ab144b0d7,
title = "Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: Novel type II inhibitor of gatekeeper mutants",
abstract = "Many clinically validated kinases, such as BCR-ABL, c-Kit, PDGFR, and EGFR, become resistant to adenosine triphosphate-competitive inhibitors through mutation of the so-called gatekeeper amino acid from a threonine to a large hydrophobic amino acid, such as an isoleucine or methionine. We have developed a new class of adenosine triphosphate competitive inhibitors, exemplified by HG-7-85-01, which is capable of inhibiting T315I-BCR-ABL (clinically observed in chronic myeloid leukemia), T670I-c-Kit (clinically observed in gastrointestinal stromal tumors), and T674I/M-PDGFRα (clinically observed in hypereosinophilic syndrome). HG-7-85-01 is unique among all currently reported kinase inhibitors in having the ability to accommodate either a gatekeeper threonine, present in the wild-type forms of these kinases, or a large hydrophobic amino acid without becoming a promiscuous kinase inhibitor. The distinctive ability of HG-7-85-01 to simultaneously inhibit both wild-type and mutant forms of several kinases of clinical relevance is an important step in the development of the next generation of tyrosine kinase inhibitors.",
author = "Ellen Weisberg and Choi, {Hwan Geun} and Arghya Ray and Rosemary Barrett and Jianming Zhang and Taebo Sim and Wenjun Zhou and Markus Seeliger and Michael Cameron and Mohammed Azam and Fletcher, {Jonathan A.} and Maria Debiec-Rychter and Mark Mayeda and Daisy Moreno and Kung, {Andrew L.} and Janne, {Pasi Antero} and Roya Khosravi-Far and Melo, {Junia V.} and Manley, {Paul W.} and Sophia Adamia and Catherine Wu and Nathanael Gray and Griffin, {James D.}",
year = "2010",
month = "5",
day = "27",
doi = "10.1182/blood-2009-11-251751",
language = "English",
volume = "115",
pages = "4206--4216",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "21",

}

TY - JOUR

T1 - Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases

T2 - Novel type II inhibitor of gatekeeper mutants

AU - Weisberg, Ellen

AU - Choi, Hwan Geun

AU - Ray, Arghya

AU - Barrett, Rosemary

AU - Zhang, Jianming

AU - Sim, Taebo

AU - Zhou, Wenjun

AU - Seeliger, Markus

AU - Cameron, Michael

AU - Azam, Mohammed

AU - Fletcher, Jonathan A.

AU - Debiec-Rychter, Maria

AU - Mayeda, Mark

AU - Moreno, Daisy

AU - Kung, Andrew L.

AU - Janne, Pasi Antero

AU - Khosravi-Far, Roya

AU - Melo, Junia V.

AU - Manley, Paul W.

AU - Adamia, Sophia

AU - Wu, Catherine

AU - Gray, Nathanael

AU - Griffin, James D.

PY - 2010/5/27

Y1 - 2010/5/27

N2 - Many clinically validated kinases, such as BCR-ABL, c-Kit, PDGFR, and EGFR, become resistant to adenosine triphosphate-competitive inhibitors through mutation of the so-called gatekeeper amino acid from a threonine to a large hydrophobic amino acid, such as an isoleucine or methionine. We have developed a new class of adenosine triphosphate competitive inhibitors, exemplified by HG-7-85-01, which is capable of inhibiting T315I-BCR-ABL (clinically observed in chronic myeloid leukemia), T670I-c-Kit (clinically observed in gastrointestinal stromal tumors), and T674I/M-PDGFRα (clinically observed in hypereosinophilic syndrome). HG-7-85-01 is unique among all currently reported kinase inhibitors in having the ability to accommodate either a gatekeeper threonine, present in the wild-type forms of these kinases, or a large hydrophobic amino acid without becoming a promiscuous kinase inhibitor. The distinctive ability of HG-7-85-01 to simultaneously inhibit both wild-type and mutant forms of several kinases of clinical relevance is an important step in the development of the next generation of tyrosine kinase inhibitors.

AB - Many clinically validated kinases, such as BCR-ABL, c-Kit, PDGFR, and EGFR, become resistant to adenosine triphosphate-competitive inhibitors through mutation of the so-called gatekeeper amino acid from a threonine to a large hydrophobic amino acid, such as an isoleucine or methionine. We have developed a new class of adenosine triphosphate competitive inhibitors, exemplified by HG-7-85-01, which is capable of inhibiting T315I-BCR-ABL (clinically observed in chronic myeloid leukemia), T670I-c-Kit (clinically observed in gastrointestinal stromal tumors), and T674I/M-PDGFRα (clinically observed in hypereosinophilic syndrome). HG-7-85-01 is unique among all currently reported kinase inhibitors in having the ability to accommodate either a gatekeeper threonine, present in the wild-type forms of these kinases, or a large hydrophobic amino acid without becoming a promiscuous kinase inhibitor. The distinctive ability of HG-7-85-01 to simultaneously inhibit both wild-type and mutant forms of several kinases of clinical relevance is an important step in the development of the next generation of tyrosine kinase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=77953636478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953636478&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-11-251751

DO - 10.1182/blood-2009-11-251751

M3 - Article

C2 - 20299508

AN - SCOPUS:77953636478

VL - 115

SP - 4206

EP - 4216

JO - Blood

JF - Blood

SN - 0006-4971

IS - 21

ER -